Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies - PubMed
4 hours ago
- #Neuroblastoma
- #Immunotherapy
- #GD2
- GD2 is a validated immunotherapeutic target for high-risk neuroblastoma.
- Dinutuximab's FDA approval in 2015 established carbohydrates as viable therapeutic targets.
- GD2 is also expressed in other malignancies like melanoma, glioma, small cell lung cancer, and sarcoma.
- Therapeutic strategies include various antibodies, bispecific antibodies, immunocytokines, CAR-T/NKT cells, and vaccines.
- Understanding each modality's strengths and limitations is crucial for designing effective combination therapies.